ReviewExpert review of neurotherapeutics2017
Investigational drugs in recent clinical trials for treatment-resistant depression.
Review in Expert review of neurotherapeutics, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 28 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
28 citing papers in PubMed, 1 synthesis or guideline pooled it, 79 citations in OpenAlex.
- Efficacy and safety of duloxetine in chronic musculoskeletal pain: a systematic review and meta-analysis.BMC musculoskeletal disorders · 2023Pooled it
- Depression clinical trials worldwide: a systematic analysis of the ICTRP and comparison with ClinicalTrials.gov.Translational psychiatry · 2024Review
- Article
- Pharmacological evidence for glutamatergic pathway involvement in the antidepressant-like effects of 2-phenyl-3-(phenylselanyl)benzofuran in male Swiss mice.Naunyn-Schmiedeberg's archives of pharmacology · 2023Article
- Recent Developments in Pharmacotherapy of Depression: Bench to Bedside.Journal of personalized medicine · 2023Review
- Microbiota-Gut-Brain Axis in Major Depression: A New Therapeutic Approach.Advances in experimental medicine and biology · 2023Review
- Novel drug developmental strategies for treatment-resistant depression.British journal of pharmacology · 2022Review
- Ketamine for the treatment of mental health and substance use disorders: comprehensive systematic review.BJPsych open · 2021Review
- Key considerations in the pharmacological management of treatment-resistant depression.Expert opinion on pharmacotherapy · 2021Article
- A general, versatile and divergent synthesis of selectively deuterated amines.Chemical science · 2021Article
- "Novel Psychopharmacology for Depressive Disorders".Advances in experimental medicine and biology · 2021Review
- Experimental Therapeutics in Treatment-Resistant Major Depressive Disorder.Journal of experimental pharmacology · 2021Review
- Bipolar depression: a major unsolved challenge.International journal of bipolar disorders · 2020Review
- Could ketamine be the answer to treating treatment-resistant major depressive disorder?General psychiatry · 2020Review
- A Review of Nonanesthetic Uses of Ketamine.Anesthesiology research and practice · 2020Review
- PI3K-AKT Signaling Activation and Icariin: The Potential Effects on the Perimenopausal Depression-Like Rat Model.Molecules (Basel, Switzerland) · 2019Article
- The influence of ketamine on drug discovery in depression.Drug discovery today · 2019Review
- The Effect of Acutely Administered Propofol on Forced Swim Test Outcomes in Mice.Innovations in clinical neuroscience · 2019Article
- In vivo electrophysiological recordings of the effects of antidepressant drugs.Experimental brain research · 2019Review
- Prognosis and improved outcomes in major depression: a review.Translational psychiatry · 2019Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 3 institutions in 1 country.
Funding
Abstract
introductionThe authors describe the medications for treatment-resistant depression (TRD) in phase II/III of clinical development in the EU and USA and provide an opinion on how current treatment can be improved in the near future. Areas covered: Sixty-two trials were identified in US and EU clinical trial registries that included six investigational compounds in recent phase III development and 12 others in recent phase II clinical trials. Glutamatergic agents have been the focus of many studies. A single intravenous dose of the glutamatergic modulator ketamine produces a robust and rapid antidepressant effect in persons with TRD; this effect continues to remain significant for 1 week. This observation was a turning point that opened the way for other, more selective glutamatergic modulators (intranasal esketamine, AVP-786, AVP-923, AV-101, and rapastinel). Of the remaining compounds, monoclonal antibodies open highly innovative therapeutic options, based on new pathophysiological approaches to depression. Expert commentary: Promising new agents are emerging for TRD treatment. Glutamatergic modulators likely represent a very promising alternative to monoaminergic antidepressant monotherapy. We could see the arrival of the first robust and rapid acting antidepressant drug in the near future, which would strongly facilitate the ultimate goal of recovery in persons with TRD.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.